Follow Us:

social twitter box white 32 social facebook box blue 32social linkedin box blue 32ISN Blog

Thursday, 05 November 2015 11:49

Efficacy of Kinkeliba in non-complicated hypertensive patients: a randomized controlled trial

By  Sidy Seck
Rate this item
(1 Vote)

 

Hypertension represents a worldwide public health issue. Combretum micranthum (kinkeliba) is a popular beverage in West Africa also widely used in traditional medicine. In vitro studies identified many compounds in kinkeliba leaves with anti-hypertensive activity but such effects have not yet been measured in clinical practice.

 

AUTHORS: 

BACKGROUND

PATIENTS AND METHODS

RESULTS

CONCLUSION


 

 

AUTHORS: 

 

SECK SM1,2, DIOP EA3, DOUPA D1,2, CISSE MM4, KA EF4, NIANG A4, DIOUF B4.

1. Faculty of Health Sciences, University Gaston berger, Saint-Louis, Senegal,

2 Unité mixte internationale UMI 3189 “Environnement Sante Societe”

3. Département de Phytochimie et Pharmacognosie, university of geneva, swizerland

4. Nephrology Department, Faculty of Medecine, University Cheikh Anta Diop, Dakar, Senegal.

 

BACKGROUND

Hypertension represents a worldwide public health issue. Combretum micranthum (kinkeliba) is a popular beverage in West Africa also widely used in traditional medicine. In vitro studies identified many compounds in kinkeliba leaves with anti-hypertensive activity but such effects have not yet been measured in clinical practice. The purpose of this study was to assess the clinical efficacy of kinkeliba in non-complicated hypertensive patients.

 

PATIENTS AND METHODS

Design: Prospective, randomized controlled trial. Settings: University Hospital of Saint-Louis. Patients: We enrolled 83 patients aged ≥18 years and diagnosed with systolic blood pressure between 140 and 179 mm Hg and a diastolic BP between 90 and 109 mm Hg) without any visceral complication and without any prior therapy. Interventions: After signing a free consent form, all enrolled patients were randomly assigned in either intervention group (low sodium diet + kinkeliba leaves 500 mg x 2/day) or control group (low sodium diet + ramipril 5 mg/day) during 04 weeks. At day 0 and day 28, investigators collected clinical and biological parameters (glycemia, serum cholesterol, triglycerides, serum creatinine and electrolytes).

Statistical analysis: Descriptive and statistics were performed using SPSS 18.0. Change in systolic/diastolic blood pressure (SBP/DBP) between baseline and the end of intervention was considered as the main outcome measures.

 

RESULTS

The two groups were comparable: group A (42 patients, mean age 54.7 ± 15.5 and group B (41 patients, mean age 56.2 ± 14.3 years). After 04 weeks, the mean systolic BP (SBP) in the kinkéliba group decreased from 152.4 ± 21.6 mm Hg at baseline to 140.6 ±15.2 mm Hg (reduction of 12.2 ± 6.6 mm Hg, p-value <0.001), whereas it changed from 156.2 ±24.3 mm Hg to 139.5 ±14.8 mm Hg (reduction of 16.7 ± 8.4 mm Hg, p-value <0.001) in the ramipril group. In the same time mean DBP changed in kinkeliba group from 95.5 ±4.3 mm Hg to 90.4 ±4.0 mm Hg after (reduction of 5.0 ±3.0, p-value <0.001), while in group B it dropped from 93.9 ±16.4 mm Hg to 87.3 ±10.3 mmHg (reduction of 6.7 ±3.6, p-value <0.001). The systolic and diastolic BP reductions were more important with ramipril compared to kinkeliba. After 04 weeks of treatment, 36.6% and 39.0% of patients normalized their BP in kinkéliba and ramipril group respectively. Three patients in kinkeliba group presented abdominal discomfort and two patients in ramipril arm complained with allergic cough.

 

CONCLUSION: 

These results support efficacy of kinkeliba leaves in patients with non-complicated hypertension. However, the amplitude of this effect is inferior to the one obtained with ramipril 5 mg/day. This small sized trial can lay the groundwork for future larger comparative studies with other antihypertensive drugs.

 

Additional Info

  • Language: English
  • Contains Audio: No
  • Content Type: Posters
  • Source: ISN
  • Event: WCN 2015
  • Year: 2015
  • Members Only: No
Read 1670 times Last modified on Thursday, 05 November 2015 13:15

Global Operations Center

Rue des Fabriques 1
1000 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact

               

Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact